Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $455.24M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 2.08M
Average 0.69M
STTK Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Shattuck Labs, Inc.NASDAQ: STTK
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $10.95M rose 10.4% year over year, ahead of the -40.4% change in trailing-twelve-month research & development. Sequentially, it rose 20.9% from the prior quarter. Over 3 fiscal years it compounded at -24.8% a year.
Context
- Research & development amounted to 3527.3% of revenue in FY2025, up 2352.5 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +10.4% holds above the trailing-twelve-month pace of -40.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 35.27M USD
- Year-over-year change
- -47.5%
- 4-year CAGR
- -11.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.27M | -47.5% |
| FY2024 | 2024-12-31 | 67.21M | -9.6% |
| FY2023 | 2023-12-31 | 74.31M | -10.4% |
| FY2022 | 2022-12-31 | 82.9M | +46.6% |
| FY2021 | 2021-12-31 | 56.56M | — |
Research & Development vs competitors
How STTK compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -40.4% is the 9th highest of 10, against a peer median of -17.1%.
- Research & development amounts to 3629.9% of revenue for STTK, versus a peer median of 63.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $241.88M USD | -19.7% | +0.6% | 63.8% | |
| LTM Mar 2026 | $145.36M USD | +345.0% | +69.4% | 1223.2% | |
| LTM Mar 2026 | $68M USD | +23.2% | +5.9% | 29.9% | |
| LTM Mar 2026 | $36.3M USD | -40.4% | -24.8% | 3629.9% | |
| LTM Jun 2026 | $31.84M USD | +107.0% | -28.2% | — | |
| LTM Mar 2026 | $30.06M USD | -37.6% | -19.5% | — | |
| LTM Sep 2026 | $23.16M USD | +47.2% | -19.1% | — | |
| LTM Mar 2026 | $16.65M USD | -23.2% | -13.5% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥13.28M CNY | -94.8% | -61.3% | — |
| LTM Mar 2026 | $7.02M USD | -17.1% | +13.9% | — | |
| Peer median (excluding STTK) | — | -17.1% | -13.5% | 63.8% | |
Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.02M | 652K | 1.66M | 5.72M | 1M |
| Cost of Revenue | 1.38M | 82.2M | 4.04M | 4.89M | 0 |
| Gross Profit | 28.64M | (81.55M) | (2.39M) | 827K | 1M |
| Gross Margin | 95.4% | -12507.2% | -143.9% | 14.5% | 100.0% |
| Research & Development | 56.56M | 82.9M | 74.31M | 67.21M | 35.27M |
| Selling, General & Admin | 18.72M | 19.68M | 19.3M | 19.08M | 17.24M |
| Operating Expenses | 73.91M | 21.78M | 89.57M | 81.39M | 52.51M |
| Depreciation & Amortization | 1.38M | 3.07M | 4.04M | 3.83M | 3.69M |
| EBITDA | (43.59M) | (98.87M) | (83.26M) | (71.58M) | (45.12M) |
| EBITDA Margin | -145.2% | -15164.4% | -5024.5% | -1251.2% | -4512.1% |
| Operating Income | (45.27M) | (103.33M) | (91.96M) | (80.57M) | (51.51M) |
| Operating Margin | -150.8% | -15848.0% | -5549.6% | -1408.3% | -5150.8% |
| Interest Income | 625K | 1.59M | 4.67M | 5.17M | 2.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 295K | 1.38M | 4.66M | 5.16M | 2.7M |
| Income Before Tax | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Pre-Tax Margin | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Net Margin | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| EPS (Basic) | (1.07) | (2.41) | (2.05) | (1.49) | (0.70) |
| EPS (Diluted) | (1.07) | (2.41) | (2.05) | (1.49) | (0.70) |
| Weighted Avg Shares | 42.03M | 42.38M | 42.6M | 50.76M | 69.58M |
| Weighted Avg Shares (Diluted) | 42.03M | 42.38M | 42.6M | 50.76M | 69.58M |
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.